Cardinal Health (NYSE:CAH) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Cardinal Health from “buy” to “strong-buy.” Other analysts remain broadly positive, with 16 Buy ratings, three Holds, and a consensus price target of $269.38.
• Cardinal Health reported quarterly EPS of $2.91, beating estimates by $0.49, while revenue rose 5.8% year over year to $63.67 billion. The company guided to fiscal 2027 EPS of $12.40–$12.60.
• Shares opened at $249.47, near their 12-month high of $259.21. Insiders sold roughly $49.6 million in stock during the past quarter, while institutional investors own 87.17% of the company.

Cardinal Health (NYSE:CAH - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Sunday, Wall Street Zen reports.

Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. raised their price objective on Cardinal Health from $215.00 to $260.00 and gave the stock a "neutral" rating in a report on Thursday, August 13th. TD Cowen lifted their target price on Cardinal Health from $275.00 to $280.00 and gave the stock a "buy" rating in a research report on Thursday, August 13th. Mizuho boosted their target price on Cardinal Health from $250.00 to $280.00 and gave the company an "outperform" rating in a report on Tuesday, October 20th. Evercore reissued an "outperform" rating and issued a $270.00 target price on shares of Cardinal Health in a research report on Wednesday, August 12th. Finally, Robert W. Baird raised their price target on Cardinal Health from $251.00 to $274.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $269.38.

Cardinal Health Trading Down 2.4%

Shares of Cardinal Health stock opened at $249.47 on Friday. The company has a fifty day simple moving average of $236.46 and a 200-day simple moving average of $223.73. Cardinal Health has a 12-month low of $158.70 and a 12-month high of $259.21. The stock has a market cap of $57.77 billion, a price-to-earnings ratio of 34.50, a PEG ratio of 1.50 and a beta of 0.50.

Cardinal Health (NYSE:CAH - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating analysts' consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The firm had revenue of $63.67 billion for the quarter, compared to the consensus estimate of $65.15 billion. During the same period last year, the firm posted $2.08 EPS. The company's revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, analysts forecast that Cardinal Health will post 12.55 earnings per share for the current fiscal year.

Insider Activity

In other Cardinal Health news, CEO Jason M. Hollar sold 44,529 shares of the business's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total value of $10,516,859.22. Following the transaction, the chief executive officer directly owned 190,603 shares of the company's stock, valued at approximately $45,016,616.54. The trade was a 18.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Deborah Weitzman sold 7,354 shares of the company's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total transaction of $1,731,499.30. Following the transaction, the chief executive officer owned 77,901 shares of the company's stock, valued at approximately $18,341,790.45. The trade was a 8.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 210,271 shares of company stock valued at $49,626,657. 0.12% of the stock is currently owned by company insiders.

Institutional Trading of Cardinal Health

Several hedge funds and other institutional investors have recently made changes to their positions in CAH. BlackRock Inc. purchased a new stake in shares of Cardinal Health in the second quarter valued at $6,293,115,000. Wellington Management Group LLP increased its stake in Cardinal Health by 247.5% in the second quarter. Wellington Management Group LLP now owns 14,860,271 shares of the company's stock valued at $3,530,206,000 after purchasing an additional 10,584,119 shares during the last quarter. Bank of America Corp DE purchased a new position in Cardinal Health during the second quarter worth about $689,066,000. Legal & General Group Plc purchased a new position in Cardinal Health during the second quarter worth about $438,870,000. Finally, Pacer Advisors Inc. lifted its position in Cardinal Health by 14.7% during the first quarter. Pacer Advisors Inc. now owns 1,565,131 shares of the company's stock worth $330,728,000 after buying an additional 200,021 shares during the period. Hedge funds and other institutional investors own 87.17% of the company's stock.

Cardinal Health Company Profile

Cardinal Health, Inc is a healthcare services and products company that supports the distribution and delivery of pharmaceuticals, medical products and related services. The company serves hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and other healthcare providers.

Its Pharmaceutical and Specialty Solutions segment distributes branded, generic and specialty pharmaceuticals, as well as consumer health products, to pharmacies and healthcare institutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.